Gland Pharma Ltd - Company Profile
Powered by 
All the sales intelligence you need on Gland Pharma Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Gland Pharma Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Gland Pharma Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Gland Pharma Ltd (Gland Pharma), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, develops and manufactures active pharmaceutical ingredients. The company's activities include the production of sterile injectables, oncology, and ophthalmic products, with a focus on complex injectables such as NCE-1s, First-to-File products, and 505(b)(2) filings. Its product offerings include liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops, long-acting injectables, suspensions, and hormonal products. Gland Pharma's products serve customers in the pharmaceutical industry, providing solutions for various medical applications. The company operates in North America, Asia, Australia, and Europe. Gland Pharma is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
Survey No.143-148,150&151, Near Gandimaisamma 'X' Roads, D.P Pally, Dundigal Gandimaisamma Manda, Hyderabad, Telangana, 500043
Website
glandpharma.com
Telephone
91 8455 699999
No of Employees
4,351
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GLAND (NSE)
Revenue (2024)
$671.3M
-0.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-9.6%
(2024 vs 2023)
Market Cap*
$4.3B
Net Profit Margin (2024)
XYZ
-8.8%
(2024 vs 2023)
* As of and is in US$
Gland Pharma Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Active Pharmaceutical Ingredients | Out-Licensing of Products |
| Injectables | Contract Manufacturing |
| Ampoules | Contract Research and Development |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Others | In June, the company received an Establishment Inspection Report from the US FDA for its JNPC facility, Visakhapatnam, India. |
| 2024 | Regulatory Approval | In May, the company secured approval from the US Food and Drug Administration for its generic Edaravone injection to treat amyotrophic lateral sclerosis. |
| 2024 | Regulatory Approval | In April, the company secured approval from the United States Food and Drug Administration for Cetrorelix Acetate for Injection, 0.25 mg/vial, Single-Dose Vial (Product). |
Competitor Comparison
| Key Parameters | Gland Pharma Ltd | Sun Pharmaceutical Industries Ltd | IPCA Laboratories Ltd | Emcure Pharmaceuticals Ltd | Abbott India Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Hyderabad | Mumbai | Mumbai | Pune | Mumbai |
| State/Province | Telangana | Maharashtra | Maharashtra | Maharashtra | Maharashtra |
| No. of Employees | 4,351 | 43,000 | 18,043 | 11,474 | 3,659 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Srinivas Sadu | Chairman | Executive Board | - | - |
| Jitendra Gangwal | Vice President - Research and Development | Senior Management | 2026 | - |
| Prasadha Rao Lysetti | Head - Operations; Senior Vice President | Senior Management | 2026 | - |
| Essaji Goolam Vahanvati | Director | Non Executive Board | 2020 | - |
| Satyanarayana Murthy Chavali | Director | Non Executive Board | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer